Compare AZIO & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AZIO | FEMY |
|---|---|---|
| Founded | 2021 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.4M | 22.4M |
| IPO Year | 2014 | 2021 |
| Metric | AZIO | FEMY |
|---|---|---|
| Price | $1.01 | $1.74 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $14.33 |
| AVG Volume (30 Days) | ★ 271.9K | 92.3K |
| Earning Date | 11-20-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 44.71 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,939,008.00 | $2,293,313.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $328.45 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 217.58 | 40.77 |
| 52 Week Low | $0.83 | $0.29 |
| 52 Week High | $1.84 | $6.29 |
| Indicator | AZIO | FEMY |
|---|---|---|
| Relative Strength Index (RSI) | 39.18 | 33.87 |
| Support Level | N/A | $0.40 |
| Resistance Level | $1.45 | $3.21 |
| Average True Range (ATR) | 0.11 | 0.21 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 40.76 | 32.73 |
Azio AI Holdings Inc is a technology infrastructure company focused on developing, owning, and operating artificial intelligence data centers, enterprise GPU compute infrastructure, digital power solutions, and digital asset mining operations. The company operates an integrated AI infrastructure business encompassing AI data center development, the sale and distribution of enterprise GPU systems and server infrastructure, high-performance computing solutions, power hosting, and strategic technology investments, serving enterprise and institutional customers across domestic and international markets.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.